Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG)

Published:2017-11-23 Issue:1 Volume:57 Page:31-37
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Skriver Signe Korsgaard¹^ORCID,Laenkholm Anne-Vibeke²,Rasmussen Birgitte Bruun³,Handler Jürgen⁴,Grundtmann Bo⁵,Tvedskov Tove Filtenborg⁶^ORCID,Christiansen Peer⁷,Knoop Ann S.¹,Jensen Maj-Britt⁸,Ejlertsen Bent¹⁸

Affiliation:

1. Department of Oncology, Rigshospitalet, Copenhagen, Denmark;

2. Department of Surgical Pathology, Zealand University Hospital, Slagelse, Denmark;

3. Department of Pathology, Herlev Hospital, Herlev, Denmark;

4. Department of Breast Surgery, Sygehus Soenderjylland, Aabenraa, Denmark;

5. Department of Breast Surgery, Ringsted Sygehus, Ringsted, Denmark;

6. Department of Breast Surgery, Rigshospitalet, Copenhagen, Denmark;

7. Breast Unit, Aarhus University Hospital/Randers Regional Hospital, Aarhus, Denmark;

8. Danish Breast Cancer Cooperative Group Secretariat, Rigshospitalet, Copenhagen, Denmark

Funder

Novartis

Danish Council for Strategic Research

Publisher

Informa UK Limited

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2017.1401228

Reference18 articles.

1. Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only

2. Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer

3. St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion

4. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes

5. Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: A systematic review

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer;Future Oncology;2024-07-29

2. A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer;Breast Cancer Research;2024-01-03

3. A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor positive breast cancer;2023-08-11

4. A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor positive breast cancer;2023-02-06

5. Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial;Journal of Clinical Oncology;2022-12-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3